Research Insights Bone Strength and Resilience CJC-1295 enhances bone mineral content and density, contributing to skeletal integrity ( 1, 3 )
Such forward-looking statements include statements regarding, among other things, the expected initiation of a Phase 1 trial of RT-114 in 2025, the potential of the RaniPill platform to enable oral delivery of multiple obesity treatments and validation of such potential through preclinical data, the target product profile of semaglutide delivered via the RaniPill capsule, the novelty, convenience and attractiveness of a once-weekly oral semaglutide treatment for patients, Ranis confidence to continue building an obesity portfolio, the potential of a once-weekly oral version of semaglutide in the RaniPill capsule to deliver the same benefits as subcutaneous delivery and to impact patients lives, the sufficiency of Ranis cash reserves, and future financial performance
We do not routinely update such information
The NAFLD activity scores (steatosis/inflammation/ballooning degeneration) were calculated using the clinical criteria outlined by Kleiner et al
I had gained all the weight I lost
A Randomized Controlled Trial of the GLP-1 Receptor Agonist Dulaglutide in Primary Polydipsia. The Journal of Clinical Investigation
